Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | C/O Adma Biologics Inc., 465 State Route 17 RAMSEY NJ 07446 |
Tel: | N/A |
Website: | https://www.admabiologics.com |
IR: | See website |
Key People | ||
Adam S. Grossman President, Chief Executive Officer, Co-Founder, Director | Jerrold B. Grossman Vice Chairman of the Board, Co-Founder | Brian Lenz Chief Financial Officer, Executive Vice President |
Business Overview |
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products. |
Financial Overview |
For the fiscal year ended 31 December 2023, ADMA Biologics Inc revenues increased 68% to $258.2M. Net loss decreased 57% to $28.2M. Revenues reflect ADMA BioManufacturing segment increase of 73% to $249.7M, Corporate segment remaining flat at $143K, United States segment increase of 67% to $244.9M, International segment increase of 74% to $13.3M. |
Employees: | 624 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,617M as of Dec 31, 2023 |
Annual revenue (TTM): | $258.22M as of Dec 31, 2023 |
EBITDA (TTM): | $29.96M as of Dec 31, 2023 |
Net annual income (TTM): | -$28.24M as of Dec 31, 2023 |
Free cash flow (TTM): | $3.82M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $79.24M as of Dec 31, 2023 |
Shares outstanding: | 228,220,236 as of Feb 23, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |